Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
RetinalGenix Technologies Inc. develops ophthalmic devices and genetic testing solutions to enable early detection, monitoring, and treatment of eye and systemic diseases such as macular degeneration, diabetic retinopathy, and Alzheimer's. Its core products include retinal imaging systems and pharmacogenetic mapping platforms, serving healthcare providers, clinics, and patients. The company focuses on innovative, non-invasive diagnostics and therapeutics to improve disease management and prevent vision loss.
This description was generated via AI from an annual report. Updated about 1 year ago.